Prophylaxis in older Canadian adults with hemophilia A: Lessons and more questions

BMC Hematology

Volumn 15, Issue 1, 2015, Pages

  Jackson, Shannon C ^a,b   Yang, Ming ^b   Minuk, Leonard ^c   Sholzberg, Michelle ^d   St Louis, Jean ^e   Iorio, Alfonso ^f   Card, Robert ^g   Poon, Man Chiu ^h  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b British Columbia Provincial Bleeding Disorders Program Adult Division   (Canada)

^c WESTERN UNIVERSITY   (Canada)

^d ST MICHAEL'S HOSPITAL   (Canada)

^e UNIVERSITY OF MONTREAL   (Canada)

^f MCMASTER UNIVERSITY   (Canada)

^g UNIVERSITY OF SASKATCHEWAN   (Canada)

^h UNIVERSITY OF CALGARY   (Canada)

Author keywords

Adults; Aging; Bleeding; Factor VIII; Hemophilia A; Prophylaxis

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8C;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANADA; CANADIAN; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG UTILIZATION; HEMOPHILIA A; HUMAN; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; SECONDARY PREVENTION; TERTIARY PREVENTION; TREATMENT DURATION;

EID: 84968339532     PISSN: None     EISSN: 20521839     Source Type: Journal    
DOI: 10.1186/s12878-015-0022-8     Document Type: Article

References (21)

1. Iorio A, Marchesini E, Marcucci M, Stobart K, Chan AK. Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. Cochrane Database Syst Rev. 2011;9:CD003429
2. Srivastava A, Brewer AK, Mauser-Bunschoten EP, Key NS, Kitchen S, Llinas A, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19:e1-47.
3. Manco-Johnson MJ, Abshire TC, Shapiro A, Riske B, Hacker M, Kilcoyne RF, et al. Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia. NEJM. 2007;357:535-44.
4. Carcao MD, Aledort L. Prophylactic factor replacement in hemophilia. Blood Rev. 2004;18:101-13.
5. Collins P, Faradji A, Morfini M, Enriquez MM, Schwartz L. Efficacy and safety of secondary prophylactic vs. on-demand sucrose-formulated recombinant factor VIII treatment in adults with severe hemophilia A: results from a 13-month crossover study. J Thromb Haemost. 2010;8:83-9.
6. Tagliaferri A, Franchini M, Coppola A, Rivolta GF, Santoro C, Rossetti G, et al. Effects of secondary prophylaxis started in adolescent and adult haemophiliacs. Haemophilia. 2008;14:945-51.
7. Tagliaferri A, Rivolta GF, Rossetti G, Pattacini C, Gandini G, Franchini M. Experience of secondary prophylaxis in 20 adolescent and adult Italian hemophiliacs. Thromb Haemost. 2006;96:542-3.
8. Biss TT, Chan AK, Blanchette VS, Iwenofu LN, McLimont M, Carcao MD. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia. 2008;14:923-30.
9. Canadian Hemophilia Assessment and Resource Management System. http://ahcdc.ca/index.php/charms.
10. Canadian Hemophilia Registry. http://www.fhs.mcmaster.ca/chr/. Accessed February 1, 2014.
11. Zappa S, McDaniel M, Marandola J, Allen G. Treatment trends for haemophilia A and haemophilia B in the United States: results from the 2010 practice patterns survey. Haemophilia. 2012;18:e140-53.
12. Siboni SM, Mannucci PM, Gringeri A, Franchini M, Tagliaferri A, Ferretti M, et al. Health status and quality of life of elderly persons with severe hemophilia born before the advent of modern replacement therapy. J Thromb Haemost. 2009;7:780-6.
13. Teitel J, Belliveau D, Blanchette V, Chan A, Klaassen R, Price V, et al. A Canadian survey of self-infusion practices in persons with haemophilia A. Haemophilia. 2012;18:e403-5.
14. Walsh CE, Valentino LA. Factor VIII prophylaxis for adult patients with severe haemophilia A: results of a US survey of attitudes and practices. Haemophilia. 2009;15:1014-21.
15. MASAC Recommendation Concerning Prophylaxis. National Hemophilia Foundation. New York, New York, USA; 2007.
16. Richards M, Williams M, Chalmers E, Liesner R, Collins P, Vidler V, et al. A United Kingdom Haemophilia Centre Doctors' Organization guideline approved by the British Committee for Standards in Haematology: guideline on the use of prophylactic factor VIII concentrate in children and adults with severe haemophilia A. Br J Haematol. 2010;149:498-507.
17. Manco-Johnson MJ, Kempton CL, Reding MT, Lissitchkov T, Goranov S, Gercheva L, et al. Randomized, controlled, parallel-group trial of routine prophylaxis vs. on-demand treatment with sucrose-formulated recombinant factor VIII in adults with severe hemophilia A (SPINART). J Thromb Haemost. 2013;11:1119-27.
18. Valentino LA, Mamonov V, Hellmann A, Quon DV, Chybicka A, Schroth P, et al. A randomized comparison of two prophylaxis regimens and a paired comparison of on-demand and prophylaxis treatments in hemophilia A management. J Thromb Haemost. 2012;10:359-67.
19. Ceponis A, Wong-Sefidan I, Glass CS, von Drygalski A. Rapid musculoskeletal ultrasound for painful episodes in adult haemophilia patients. Haemophilia. 2013;19:790-8.
20. Khawaji M, Astermark J, Berntorp E. Lifelong prophylaxis in a large cohort of adult patients with severe haemophilia: a beneficial effect on orthopedic outcome and quality of life. European J Haematol. 2013;88:329-35.
21. Fischer K, Carlsson KS, Petrini P, Molmstrom M, Ljung RC, Van den Berg HM, et al. Intermediate-dose versus high dose prophylaxis for severe hemophilia: comparing outcome and costs since the 1970s. Blood. 2013;122:1129-36.